Open access · OA
via OpenAlex
Cellular senescence and cancer
The Journal of Pathology · 1999 · ▲ 365 citations
Abstract
The proliferative lifespan of normal mammalian cells is limited by intrinsic controls, which desensitize the cell-cycle machinery to extrinsic stimulation after a given number of cell divisions. One underlying clock driving this process of 'replicative senescence(definition)' is the progressive erosion of chromosome telomeres, which occurs with each round of DNA replication. This appears to trigger growth inhibition via activation of the tumour suppressor gene (TSG) product, p53, and the consequent up-regulation of the cell-cycle inhibitor p21WAF1. Other inhibitory pathways are also activated (possibly by additional clocks), including the TSG p16INK4a and the less well-defined complementation group genes. Loss of one pathway can be compensated, after a limited extension of lifespan, by further up-regulation of the others, so that to escape mortality a developing tumour must overcome multiple 'proliferative lifespan barriers' (PLBs) by successive genetic events, each conferring a new wave of clonal expansion. This provides one explanation for the existence of multiple genetic abnormalities in human cancers; furthermore, the diversity in the nature and timing of these PLBs between different cell types may explain the variation in the spectrum of abnormalities observed between the corresponding cancers. Even if all senescence pathways are inactivated, immortalization can only be achieved if erosion of telomeres is halted, before their end-protecting function is lost. This usually requires either activation of telomerase during tumour development, if the cell of origin is telomerase-negative, or up-regulation if the normal cell already has some activity, but not enough to prevent erosion. In either case, cancers often maintain near-critical telomere(definition) lengths; hence pharmacological inhibition of telomerase remains an attractive approach to the selective killing of tumour cells.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/(sici)1096-9896(199901)187:1<100::aid-path236>3.0.co;2-t
- Canonical
- link ↗
- Fetched
- 2026-07-07 MST
Cite this
APA
Wynford‐Thomas, D. (1999). Cellular senescence and cancer. <em>The Journal of Pathology</em>. https://doi.org/10.1002/(sici)1096-9896(199901)187:1<100::aid-path236>3.0.co;2-t
Vancouver
Wynford‐Thomas D. Cellular senescence and cancer. The Journal of Pathology. 1999. doi:10.1002/(sici)1096-9896(199901)187:1<100::aid-path236>3.0.co;2-t.
BibTeX
@article{david1999Cellul,
title = {Cellular senescence and cancer},
author = {David Wynford‐Thomas},
journal = {The Journal of Pathology},
year = {1999},
doi = {10.1002/(sici)1096-9896(199901)187:1<100::aid-path236>3.0.co;2-t},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
InTech eBooks 2017
Open access · CC-BY
Telomerase Inhibitors and Activators: Pharmaceutical Importance
biorxiv 2024
Preprint · CC-BY
Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic Imaging
PubMed 1996
Preprint
The role of telomeres and telomerase in human cancer.
Nucleic Acids Research 2002
Open access · OA
Natural and pharmacological regulation of telomerase
Current Stem Cell Research & Therapy 2020
Citation only
Regulation and Effect of Telomerase and Telomeric Length in Stem Cells
Frontiers in Oncology 2012
Open access · CC-BY